Three Key Considerations for Healthcare Companies Raising Capital in Today’s Fundraising Environment

Suchira Sharma
May 11
Updated: Aug 1
Noteworthy

The healthcare industry is ever-evolving, and healthcare CEOs looking to raise money from investors in 2023 need to be well-prepared to navigate the current venture capital landscape. While overall investment in the healthcare industry was robust in 2020 and 2021, demand has cooled significantly in 2022 and so far through 2023. Investors are becoming more discerning and selective in their investments.

Here are three key considerations for healthcare companies raising capital in today’s environment to maximize chances for a successful fundraise:

Prioritize Capital Raised and Investor Alignment

In order to maximize success for a fundraise, CEOs should be focused on demonstrating a clear value proposition, path to profitability, and proof of leverage in the company’s P&L at the unit economic level. In this environment, raising adequate capital, especially from well-capitalized and strategically aligned investors, may be more important than seeking to optimize valuation. Investors are more likely to fund a company that has a runway through clear de-risking milestones, and better yet, a clear path to profitability, with well-funded investors around the table.

Communicate Regularly with Existing Investors to Understand Their Reserves

Existing investors, or insiders, often reserve capital for future rounds of financing. However, in a constrained environment, these investors may need to reallocate reserves to other portfolio companies, or even shift strategies entirely. In these cases, it becomes important to quickly identify which investors may be unable or unwilling to participate in future financings. Once those groups are identified, CEOs can work with a dedicated secondary investor who may be willing to step into the “pro rata” responsibility of these groups, refreshing the syndicate and providing a fresh source of capital.

Think Creatively About Employee Compensation

The terms for a new round of equity financing may include a refreshing of the company’s option pool. However, in cases where a company is raising a convertible note or debt, or in cases where augmenting the pool isn’t an option, companies can consider giving employees a liquidity option for their shares. A secondary partner can work with a company to purchase shares from employees for cash. This can help reward and retain employees, while also relieving pent-up demand for liquidity.

In conclusion, CEOs seeking to raise money from healthcare investors in 2023 should be well-prepared and knowledgeable about the current venture capital fundraising environment. They should prioritize capital raised over the valuation of the round, focus on investor alignment (both existing and new), and think creatively about employee compensation. By considering these factors, CEOs can increase their chances of securing funding and setting their companies for success in 2023’s dynamic fundraising environment.

Disclaimer

The information contained herein is for informational and educational purposes only, does not constitute an offer to sell or the solicitation of an offer to purchase any security, is not presented with a view to providing investment advice with respect to any security, or making any claim as to the past, current or future performance thereof, and Revelation expressly disclaims the use of this document for such purposes. Each recipient should consult its own advisers as to legal, business, tax and other related matters concerning any investment.

Statements contained herein are based on current expectations, estimates, projections, opinions, views and beliefs of Revelation as of the date of this document. Such statements involve known and unknown risks and uncertainties, and undue reliance should not be placed thereon. Neither Revelation nor any of its affiliates makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein and nothing contained herein should be relied upon as a promise or representation as to past or future performance. Revelation and its members, partners, stockholders, managers, directors, officers, employees and agents do not have any obligation to update any information included herein. Certain information contained herein has been obtained from published and non-published sources and/or prepared by third-parties, and in certain cases has not been updated through the date hereof. While such information is believed to be reliable for the purposes of this document, Revelation assumes no responsibility for the accuracy or completeness of such information and such information has not been independently verified by it. The inclusion of any third-party firm and/or company names, brands and/or logos does not imply any affiliation with these firms or companies. None of these firms or companies have endorsed Revelation or any affiliated entities or personnel. Recipients of this document agree that none of Revelation or its affiliates or its or their respective partners, members, employees, officers, directors, agents, or representatives shall have any liability for any misstatement or omission of fact or any opinion expressed herein.

Certain information contained herein constitutes “forward-looking statements,” which can be identified by the use of terms such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “projects,” “future,” “targets,” “intends,” “plans,” “believes,” “estimates” (or the negatives thereof) or other variations thereon or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, some of which are beyond the control of Revelation. Actual results, performance, prospects or opportunities could differ materially from those expressed in or implied by the forward-looking statements. Additional risks of which Revelation is not currently aware also could cause actual results to differ. In light of these risks, uncertainties and assumptions, recipients should not place undue reliance on any forward-looking statements. The forward-looking events discussed in this document may not occur. Revelation undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The delivery of this document at any time shall not under any circumstances create an implication that the information contained herein is correct as of any time after the earlier of the relevant date specified herein or the date of this document.

Any offer, sale or solicitation of interests in any private investment vehicle offered by Revelation in the future (each, a “Fund”) will be made only pursuant to such Fund’s confidential private placement memorandum (the “Memorandum”), limited partnership agreement and subscription agreement, and will be subject to the terms and conditions contained in such documents in accordance with applicable securities laws. This document is qualified in its entirety by reference to any such Fund’s Memorandum, including without limitation all of the cautionary statements and risk factors set forth therein, the applicable limited partnership agreement and the applicable subscription agreement related thereto, copies of all of which can be made available in the future to qualified investors upon request and should be read carefully prior to any investment in any such Fund.